Art. -Nr.: HY-112218

MIK665

(Synonyms: S-64315)

18 Cited Publications

Kundenbewertung

Based on 18 publication(s) in Google Scholar

MIK665 (S-64315), derived from S63845, is a myeloid cell leukemia sequence 1 (MCL1) inhibitor. MIK665 has an IC₅₀ of 1.81 nM for MCL1.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.11%
CAS. Nr.: 1799631-75-6
Formel: C₄₇H₄₄ClFN₆O₆S
Molecular Weight:875.41

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

MIK665 Chemical Structure

CAS. Nr.: 1799631-75-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Clinical Trial
Chemical Information
Publications (18)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

MIK665 (S-64315), derived from S63845, is a myeloid cell leukemia sequence 1 (MCL1) inhibitor^[1]. MIK665 has an IC₅₀ of 1.81 nM for MCL1^[2].

IC₅₀ & Target^[1]

Mcl-1

1.81 nM (IC₅₀)

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
NCI-H929	IC₅₀	1.7 nM Compound: 9m; S64315; MIK665	Antiproliferative activity against human NCI-H929 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human NCI-H929 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33146521]

In Vitro

MIK665 (S-64315) has similar synergistic effects as S63845, when combined with ABT-199. The combination S64315 (0.156-10 μM) and ABT-199 (625 nM) has similar efficacy in reducing the cell viability of representative melanoma lines (MB2141, MB3616, MB3961, MB4667, A375, and 1205Lu cells)^[1].
MIK665 is extracted from patent WO2016207225A1, compound Preparation 13, and inhibits H929 cell with an IC₅₀ of 250 nM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1799631-75-6
Appearance Solid
Molecular Weight 875.41
Formel C₄₇H₄₄ClFN₆O₆S
Color White to off-white
SMILES

OC([C@@H](CC(C=CC=C1)=C1OCC2=CC=NC(C3=CC=CC=C3OC)=N2)OC4=C5[C@]([C@]6=C(C)C(Cl)=C(OCCN7CCN(C)CC7)C=C6)=C(C8=CC=C(F)C=C8)SC5=NC=N4)=O
Synonyms

S-64315
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (18)

All Flow CytometryIn Vivo Efficacy StudyWBCell Imaging/StainingBio/Physico-chemical AssayCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Cell Stem Cell

Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. [Abstract]

2026 Jun 4;33(6):982-999.e8. PMID: 42102807
Nat Commun

Small round cell sarcoma tumoroid biobank reveals CIC::DUX4 sarcoma vulnerability to MCL-1 inhibition. [Abstract]

2025 Aug 21;16(1):7689. PMID: 40841360
Nat Commun

Patient-derived tumoroids from CIC::DUX4 rearranged sarcoma identify MCL1 as a therapeutic target. [Abstract]

2025 Aug 21;16(1):7688. PMID: 40841513

MIK665 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 21;16(1):7688. [Abstract]

MIK665 (S-64315) (10-50 nM; 24 h) effectively and rapidly induced cell death of CDS-ZH003.

MIK665 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 21;16(1):7688. [Abstract]

MIK665 (S-64315) (20 mg/kg; i.v.; twice a week for 3 weeks) regressed tumors and significantly prolonged the survival of NSG mice.
Mol Cell

Anti-apoptotic MCL-1 promotes long-chain fatty acid oxidation through interaction with ACSL1. [Abstract]

2024 Apr 4;84(7):1338-1353.e8. PMID: 38503284

MIK665 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2024 Apr 4;84(7):1338-1353.e8. [Abstract]

MIK665 (S-64315) (500 nM) stabilized MCL-1 of 293T cellsbut repressed the ability of human MCL-1 to co-precipitate with ACSL1 and BIM.

MIK665 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2024 Apr 4;84(7):1338-1353.e8. [Abstract]

MIK665 (S-64315) (500 nM) significantly repressed the utilization of oleate-containing lipid droplets in hMCL-1 MEFs.

MIK665 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2024 Apr 4;84(7):1338-1353.e8. [Abstract]

MCL-1 inhibitor MIK665 (S-64315) (50 mg/kg; i.v.; once daily for 5 d) significantly repressed palmitate oxidation in heart mitochondria from C57BL/6J mice.
Cell Death Dis

Both direct and indirect suppression of MCL1 synergizes with BCLXL inhibition in preclinical models of gastric cancer. [Abstract]

2025 Mar 12;16(1):170. PMID: 40075071
Cell Death Dis

MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade. [Abstract]

2024 Mar 8;15(3):198. PMID: 38459020
Cell Death Dis

MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. [Abstract]

2020 Jun 8;11(6):443. PMID: 32513939

MIK665 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2020 Jun 8;11(6):443. [Abstract]

S64315+A-1331852 and S64315+ABT-263 significantly reduces cell viability compared with DMSO or with single drug treated conditions in all melanoma cell lines at sub-micromolar doses.
Cancer Lett

High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1/BCL-XL inhibition against Ewing sarcoma. [Abstract]

2023 Feb 1:554:216028. PMID: 36462556
J Invest Dermatol

Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics. [Abstract]

2022 Jul;142(7):1912-1922.e7. PMID: 34942200
Pharmaceuticals (Basel)

A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine. [Abstract]

2021 Jul 30;14(8):749. PMID: 34451846
Cancers

Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma. [Abstract]

2020 Aug 5;12(8):2182. PMID: 32764384
EJC Paediatr Oncol

2024 Jun 3.
Melanoma Res

Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma. [Abstract]

2023 Oct 1;33(5):345-356. PMID: 37467061
bioRxiv

2025 Oct 10.
Leiden University

2025.
Patent

US20230116602A1.
Patent

US20220347180A1.
University of Colorado

2020 Dec.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 125 mg/mL (142.79 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.1423 mL

5.7116 mL

11.4232 mL

5 mM

0.2285 mL

1.1423 mL

2.2846 mL

10 mM

0.1142 mL

0.5712 mL

1.1423 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (2.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (2.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Mukherjee N, et al. Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma. Cancers (Basel). 2020;12(8):2182. Published 2020 Aug 5. [Content Brief]

[2]. Zoltán SZLÁVIK, et al. New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them. WO2016207225A1.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.1423 mL	5.7116 mL	11.4232 mL	28.5580 mL
	5 mM	0.2285 mL	1.1423 mL	2.2846 mL	5.7116 mL
	10 mM	0.1142 mL	0.5712 mL	1.1423 mL	2.8558 mL
	15 mM	0.0762 mL	0.3808 mL	0.7615 mL	1.9039 mL
	20 mM	0.0571 mL	0.2856 mL	0.5712 mL	1.4279 mL
	25 mM	0.0457 mL	0.2285 mL	0.4569 mL	1.1423 mL
	30 mM	0.0381 mL	0.1904 mL	0.3808 mL	0.9519 mL
	40 mM	0.0286 mL	0.1428 mL	0.2856 mL	0.7140 mL
	50 mM	0.0228 mL	0.1142 mL	0.2285 mL	0.5712 mL
	60 mM	0.0190 mL	0.0952 mL	0.1904 mL	0.4760 mL
	80 mM	0.0143 mL	0.0714 mL	0.1428 mL	0.3570 mL
	100 mM	0.0114 mL	0.0571 mL	0.1142 mL	0.2856 mL

Keywords

MIK665

18 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

MIK665

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Publications Citing Use of MedChemExpress (MCE) MIK665

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (18)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

MIK665

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Publications Citing Use of MedChemExpress (MCE) MIK665

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (18)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

MIK665 Related Classifications

HY-112218 Related Classifications